Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials
Most Cited Paper
in Heart Failure Treatment and Management
18 Months Post-Publication
Class of 2026
“Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials”
A research intelligence initiative by Pepkio
pri.pepkio.com/top-papers/heart-failure-treatment-and-management/2026/
Topics
Semaglutide · Heart failure with preserved ejection fraction · Heart failure with mildly reduced ejection fraction · GLP-1 receptor agonist · Pooled analysis · Randomized controlled trial · SELECT trial · FLOW trial · STEP-HFpEF trial · STEP-HFpEF DM trial · Placebo · Cardiovascular events · Obesity · Type 2 diabetes · Chronic Kidney Disease · Left ventricular ejection fraction · weight loss · Heart failure hospitalization · Cardiovascular death · All-Cause Mortality · Kansas City Cardiomyopathy Questionnaire · Patient-reported outcomes · Composite Endpoint · Renal outcomes · Cardiometabolic disease · Body weight reduction · Heart failure symptoms · Diabetes management · Semaglutide cardioprotective effects · Secondary analysis
Share
Cite this ranking
Pepkio Research Index (PRI). Topics and Trends in Most Cited Heart Failure Treatment and Management Papers, Class of 2026. https://pri.pepkio.com/top-papers/heart-failure-treatment-and-management/2026. Accessed 2026-07-13. Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459